Research Topics
| J A KanisSummaryAffiliation: University of Sheffield Country: UK Publications
| Collaborators
|
Detail Information
Publications
FRAX(®) with and without bone mineral densityJohn A Kanis
WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Beech Hill Road, Sheffield S10 2RX, UK
Calcif Tissue Int 90:1-13. 2012....
The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and womenJ A Kanis
WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Beech Hill Road, Sheffield, S10 2RX, UK
Osteoporos Int 18:1033-46. 2007..The combination of clinical risk factors and BMD provide higher specificity and sensitivity than either alone. INTRODUCTION AND HYPOTHESES: To develop a risk assessment tool based on clinical risk factors (CRFs) with and without BMD...
The use of multiple sites for the diagnosis of osteoporosisJ A Kanis
WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Beech Hill Road, S10 2RX Sheffield, UK
Osteoporos Int 17:527-34. 2006..It has been suggested that bone mineral density (BMD) measurements should be made at multiple sites, and that the lowest T-score should be taken for the purpose of diagnosing osteoporosis...
Cost-effectiveness of raloxifene in the UK: an economic evaluation based on the MORE studyJ A Kanis
WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Sheffield, UK
Osteoporos Int 16:15-25. 2005..In relation to threshold values that are recommended in the UK, the analysis suggests that raloxifene is cost-effective in the treatment of postmenopausal women at an increased risk of vertebral fractures...
Intervention thresholds for osteoporosis in the UKJohn A Kanis
Centre for Metabolic Bone Diseases WHO Collaborating Centre, University of Sheffield Medical School, Sheffield, UK
Bone 36:22-32. 2005....
Requirements for DXA for the management of osteoporosis in EuropeJ A Kanis
WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Beech Hill Road, Sheffield, S10 2RX, UK
Osteoporos Int 16:229-38. 2005..The total direct costs were estimated at 31.7 billion Euros (21.165 billion UK pounds), which were expected to increase to 76.7 billion Euros (51.1 billion UK pounds) in 2050 based on the expected changes in the demography of Europe...
Alcohol intake as a risk factor for fractureJohn A Kanis
WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Beech Hill Road, Sheffield, S10 2RX, UK
Osteoporos Int 16:737-42. 2005..We conclude that reported intake of alcohol confers a risk of some importance beyond that explained by BMD. The validation of this risk factor on an international basis permits its use in case-finding strategies...
A meta-analysis of previous fracture and subsequent fracture riskJ A Kanis
WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Sheffield, UK
Bone 35:375-82. 2004..Its validation on an international basis permits the use of this risk factor in case finding strategies...
Cost-effectiveness of risedronate for the treatment of osteoporosis and prevention of fractures in postmenopausal womenJ A Kanis
WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Beech Hill Road, S10 2RX, Sheffield, UK
Osteoporos Int 15:862-71. 2004..5 SD) but without a prior vertebral fracture, treatment exceeded the threshold for cost-effectiveness. However, if an additional, independent risk factor was assumed (e.g., corticosteroid use) treatment became cost-effective...
Smoking and fracture risk: a meta-analysisJ A Kanis
WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Beech Hill Road, Sheffield, S10 2RX, UK
Osteoporos Int 16:155-62. 2005..Its validation on an international basis permits the use of this risk factor in case finding strategies...
Intervention thresholds for osteoporosis in men and women: a study based on data from SwedenJohn A Kanis
Centre for Metabolic Bone Diseases WHO Collaborating Centre, University of Sheffield Medical School, Beech Hill Road, Sheffield, S10 2RX, UK
Osteoporos Int 16:6-14. 2005....
Ten-year probabilities of clinical vertebral fractures according to phalangeal quantitative ultrasonographyJ A Kanis
WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Beech Hill Road, Sheffield, S10 2RX, UK
Osteoporos Int 16:1065-70. 2005..The use of absolute risk permits information from different types of bone mineral measurements to be applied for the assessment of patients, either alone or in combination with other independent risk factors...
Case finding for the management of osteoporosis with FRAX--assessment and intervention thresholds for the UKJ A Kanis
WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Beech Hill Road, Sheffield, S10 2RX, UK
Osteoporos Int 19:1395-408. 2008..Assessment and intervention thresholds are developed and proposed in men aged over 50 years and postmenopausal women for the UK based on fracture probability from the WHO fracture risk assessment tool (FRAX)...
Guidance for the adjustment of FRAX according to the dose of glucocorticoidsJ A Kanis
WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Beech Hill Road, Sheffield S102RX, UK
Osteoporos Int 22:809-16. 2011..A relatively simple adjustment of conventional FRAX estimates of probabilities of hip fracture and a major osteoporotic fracture can be applied to modulate the risk assessment with knowledge of the dose of glucocorticoids...
A meta-analysis of the efficacy of raloxifene on all clinical and vertebral fractures and its dependency on FRAXJohn A Kanis
WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield, Beech Hill Road, Sheffield, UK
Bone 47:729-35. 2010..There was no significant effect on non-vertebral fracture...
Development and use of FRAX in osteoporosisJ A Kanis
WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Beech Hill Road, Sheffield, S10 2RX, UK
Osteoporos Int 21:S407-13. 2010..The FRAX tool integrates information on fracture risk from clinical risk factors with or without the use of BMD and can be used to improve the targeting of individuals at high fracture risk...
Partial adherence: a new perspective on health economic assessment in osteoporosisJ A Kanis
WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Beech Hill Road, Sheffield S10 2RX, UK
Osteoporos Int 22:2565-73. 2011..This review highlights a number of avenues for further research, such as improved definition of thresholds of compliance and persistence, as well as gap length, offset times, and fraction of benefit...
How to decide who to treatJ A Kanis
WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield, UK
Best Pract Res Clin Rheumatol 23:711-26. 2009..The tool increases sensitivity without trading specificity and is now being used in the re-appraisal of clinical guidelines...
The effects of a FRAX revision for the USAJ A Kanis
WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Sheffield, UK
Osteoporos Int 21:35-40. 2010..With the revised tool, there were strong correlations (r > 0.99) between versions 2.0 and 3.0 for FRAX estimates of fracture probability, but the revised models gave lower probability estimates...
A meta-analysis of the effect of strontium ranelate on the risk of vertebral and non-vertebral fracture in postmenopausal osteoporosis and the interaction with FRAX(®)J A Kanis
WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Beech Hill Road, Sheffield, S10 2RX, South Yorkshire, UK
Osteoporos Int 22:2347-55. 2011..Hazard ratios for the effect of strontium ranelate on the fracture outcome did not change significantly with increasing fracture probability...
Approaches to the targeting of treatment for osteoporosisJohn A Kanis
WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Sheffield, UK
Nat Rev Rheumatol 5:425-31. 2009..The tool increases sensitivity without trading specificity, and is now being used in the reappraisal of clinical guidelines...
Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAXJohn A Kanis
WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield, Beech Hill Road, Sheffield S10 2RX, UK
Bone 44:1049-54. 2009..No significant effect was noted on the risk of clinical fractures, but fracture risk reduction was reported in a post hoc subgroup analysis in a high risk group categorised on the basis of BMD and prior fracture...
Towards a diagnostic and therapeutic consensus in male osteoporosisJ A Kanis
WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Beech Hill Road, Sheffield, UK
Osteoporos Int 22:2789-98. 2011..The consensus views on osteoporosis in men are reported...
FRAX and the assessment of fracture probability in men and women from the UKJ A Kanis
WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Beech Hill Road, Sheffield S10 2RX, UK
Osteoporos Int 19:385-97. 2008..A fracture risk assessment tool (FRAX) is developed based on the use of clinical risk factors with or without bone mineral density tests applied to the UK...
European guidance for the diagnosis and management of osteoporosis in postmenopausal womenJ A Kanis
WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Beech Hill Road, Sheffield S10 2RX, UK
Osteoporos Int 19:399-428. 2008..Guidance is provided in a European setting on the assessment and treatment of postmenopausal women with or at risk from osteoporosis...
A family history of fracture and fracture risk: a meta-analysisJ A Kanis
Centre for Metabolic Bone Diseases WHO Collaborating Centre, University of Sheffield Medical School, Sheffield, UK
Bone 35:1029-37. 2004..Its identification on an international basis supports the use of this risk factor in case-finding strategies...
The burden of osteoporotic fractures: a method for setting intervention thresholdsJ A Kanis
WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Beech Hill Road, Sheffield S10 2RX, UK
Osteoporos Int 12:417-27. 2001....
Ten-year fracture probability identifies women who will benefit from clodronate therapy--additional results from a double-blind, placebo-controlled randomised studyE V McCloskey
WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield, Sheffield, UK
Osteoporos Int 20:811-7. 2009..This study demonstrates that the estimation of an individual's 10-year probability of fracture by the FRAX algorithm identifies patients at high risk of fracture who will respond to bisphosphonate therapy...
Ten year probabilities of osteoporotic fractures according to BMD and diagnostic thresholdsJ A Kanis
WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, UK
Osteoporos Int 12:989-95. 2001..Intervention thresholds based on hip BMD T-scores are similar between sexes...
Cost-effectiveness of preventing hip fracture in the general female populationJ A Kanis
Centre for Metabolic Bone Diseases (WHO Collaborating Centre, University of Sheffield Medical School, Beech Hill Road, Sheffield S10 2RX, UK
Osteoporos Int 12:356-61. 2001..We conclude that segments of the apparently healthy population could be advantaged by treatment if efficacy were supported by randomized controlled studies...
The risk and burden of vertebral fractures in SwedenJ A Kanis
Centre for Metabolic Bone Diseases, WHO Collaborating Centre, University of Sheffield Medical School, Beech Hill Road, Sheffield, S10 2RX, UK
Osteoporos Int 15:20-6. 2004..We conclude that vertebral fractures have a major personal and societal impact that needs to be recognised in algorithms for assessment of risk and in health economic strategies for osteoporosis...
Can fall risk be incorporated into fracture risk assessment algorithms: a pilot study of responsiveness to clodronateK Kayan
WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield, Beech Hill Road, Sheffield S10 2RX, UK
Osteoporos Int 20:2055-61. 2009..Fall risk does not significantly impact on the efficacy of the bisphosphonate clodronate in reducing the incidence of fracture...
Diagnosis of osteoporosis and fracture threshold in menJ A Kanis
WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, UK
Calcif Tissue Int 69:218-21. 2001..Although data are limited, prior fragility fractures increase subsequent fracture risks in both men and women. These studies suggest that the same BMD criteria used to diagnose osteoporosis in women can be applied to men...
A high incidence of vertebral fracture in women with breast cancerJ A Kanis
WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, UK
Br J Cancer 79:1179-81. 1999..3-9.9], and 20-fold higher in women with soft-tissue metastases without evidence of skeletal metastases (OR, 22.7; 95% CI, 9.1-57.1). We conclude that vertebral fracture risk is markedly increased in women with breast cancer...
A new approach to the development of assessment guidelines for osteoporosisJ A Kanis
WHO Centre for Metabolic Bone Diseases, University of Sheffield, UK
Osteoporos Int 13:527-36. 2002
Epidemiology of osteoporosis and fracture in menJ A Kanis
WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Beech Hill Rd, Sheffield, United Kingdom S10 2RX
Calcif Tissue Int 75:90-9. 2004
Risedronate decreases fracture risk in patients selected solely on the basis of prior vertebral fractureJ A Kanis
Centre for Metabolic Bone Diseases WHO Collaborating Centre, University of Sheffield Medical School, Beech Hill Road, Sheffield S10 2RX, UK
Osteoporos Int 16:475-82. 2005....
Pitfalls in the external validation of FRAXJ A Kanis
WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Beech Hill Road, Sheffield S10 2RX, UK
Osteoporos Int 23:423-31. 2012..Recent studies have evaluated the performance of FRAX® in independent cohorts. The interpretation of most is problematic for reasons summarised in this perspective...
BMD, clinical risk factors and their combination for hip fracture preventionH Johansson
WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Beech Hill Road, Sheffield, S10 2RX, UK
Osteoporos Int 20:1675-82. 2009....
The components of excess mortality after hip fractureJ A Kanis
WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Beech Hill Road, Sheffield S10 2RX, UK
Bone 32:468-73. 2003..Hip fracture was a more common cause for mortality than pancreatic or stomach cancer. Thus, interventions that decreased hip fracture rate by, say, 50% would avoid 0.75% or more of all deaths...
Risk of hip fracture according to the World Health Organization criteria for osteopenia and osteoporosisJ A Kanis
WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Sheffield, UK
Bone 27:585-90. 2000..The decrease in relative risk with age is, however, associated with an increase in absolute risk. Thus, for clinical use, the expression of absolute risks may be preferred to relative risks...
Effects of clodronate on vertebral fracture risk in osteoporosis: a 1-year interim analysisE McCloskey
The WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Sheffield, UK
Bone 28:310-5. 2001..We conclude that clodronate 800 mg daily is effective in preventing bone loss, and at 1 year, there is a trend consistent with antifracture efficacy in patients with established osteoporosis regardless of causation...
Interpretation and use of FRAX in clinical practiceJ A Kanis
WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Beech Hill Road, Sheffield, S10 2RX, UK
Osteoporos Int 22:2395-411. 2011..Its use in fracture risk prediction has strengths, but also limitations of which the clinician should be aware and are the focus of this review..
A systematic review of hip fracture incidence and probability of fracture worldwideJ A Kanis
WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Beech Hill Road, Sheffield, UK
Osteoporos Int 23:2239-56. 2012..There was a greater than 10-fold variation in hip fracture risk and fracture probability between countries...
A reappraisal of generic bisphosphonates in osteoporosisJ A Kanis
WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield, UK University of Sheffield Medical School, Beech Hill Road, Sheffield S10 2RX, UK
Osteoporos Int 23:213-21. 2012..The competitive price of generic bisphosphonates has had a marked effect on practice guidelines, but an increasing body of evidence suggests that they have more limited effectiveness than generally assumed...
Ten-year risk of osteoporotic fracture and the effect of risk factors on screening strategiesJ A Kanis
WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Sheffield, UK
Bone 30:251-8. 2002..0/SD). Such gradients might be achieved with the use of multiple risk factors to identify patients at risk...
Glucocorticoid-induced osteoporosis: a systematic review and cost-utility analysisJ A Kanis
WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, UK
Health Technol Assess 11:iii-iv, ix-xi, 1-231. 2007..To determine whether strategies can be devised for the assessment and treatment of glucocorticoid-induced osteoporosis (GIO)...
A FRAX® model for the assessment of fracture probability in BelgiumH Johansson
WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Beech Hill Road, Sheffield, S10 2RX, UK
Osteoporos Int 22:453-61. 2011..A country-specific FRAX® model was developed from the epidemiology of fracture and death in Belgium. Fracture probabilities were identified that corresponded to currently accepted reimbursement thresholds...
Increasing age- and sex-specific rates of hip fracture in Mexico: a survey of the Mexican Institute of Social SecurityH Johansson
WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Beech Hill Road, Sheffield, S10 2RX, UK
Osteoporos Int 22:2359-64. 2011..If the age-specific incidence of hip fracture continues, the number of hip fractures would increase by a further 46%...
Long-term follow-up of a prospective, double-blind, placebo-controlled randomized trial of clodronate in multiple myelomaE V McCloskey
WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield, Medical School, Sheffield, UK
Br J Haematol 113:1035-43. 2001..These observations, however, require confirmation in prospective clinical trials...
Study design in osteoporosis: a European perspectiveJ A Kanis
WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Sheffield, United Kingdom
J Bone Miner Res 18:1133-8. 2003..If fracture studies are required by regulatory agencies, there is still a requirement for placebo-controlled studies, although perhaps of shorter duration than demanded at present...
Intervention thresholds for osteoporosisJ A Kanis
Centre for Metabolic Bone Diseases (WHO Collaborating Centre, University of Sheffield Medical School, Sheffield, UK
Bone 31:26-31. 2002....
A randomised double-blind comparison of intravenous pamidronate and clodronate in the hypercalcaemia of malignancyO P Purohit
YCRC Department of Clinical Oncology, Weston Park Hospital, Sheffield, UK
Br J Cancer 72:1289-93. 1995..We conclude that both agents are effective in the management of hypercalcaemia of malignancy. At the doses studied, the effects of pamidronate are more complete and longer lasting than those of clodronate...
Optimal age for preventing osteoporosis after menopause depends on effects of stopping treatmentF Caulin
Centre for Metabolic Bone Diseases (WHO Collaborating Centre, University of Sheffield Medical School, Beech Hill Road, Sheffield S10 2RX, UK
Bone 30:754-8. 2002..This figure rose to 23 per 1000 at the age of 70 years. We conclude that, although uncertainty exists concerning the offset of effect of treatments, treatments should be optimally given to women without prior fractures in later life...
Treatment of established osteoporosis: a systematic review and cost-utility analysisJ A Kanis
WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Sheffield, UK
Health Technol Assess 6:1-146. 2002
European guidance for the diagnosis and management of osteoporosis in postmenopausal womenJ A Kanis
WHO Collaborating Centre, UK University of Sheffield Medical School, Sheffield, UK
Osteoporos Int 24:23-57. 2013..Guidance is provided in a European setting on the assessment and treatment of postmenopausal women at risk of fractures due to osteoporosis...
The clinical and cost considerations of bisphosphonates in preventing bone complications in patients with metastatic breast cancer or multiple myelomaE V McCloskey
WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, England
Drugs 61:1253-74. 2001..It is not known whether more potent bisphosphonates will deliver greater clinical efficacy in the future...
Performance of clinical referral criteria for bone densitometry in patients under 65 years of age assessed by spine bone mineral densityK Kayan
WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield, Sheffield, UK
Postgrad Med J 79:581-4. 2003..Criteria like loss of height and/or spine curvature perform relatively poorly, reflecting the need for further investigation to better identify those needing BMD assessment...
Uncertain future of trials in osteoporosisJ A Kanis
WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Sheffield, UK
Osteoporos Int 13:443-9. 2002..In this review we argue that, if new agents are to be developed, there is still a place for the placebo-controlled trial. A move to studies of equivalence or non-inferiority raises more problems than it resolves...
Assessing the risk of vertebral osteoporosisJ A Kanis
Centre for Metabolic Bone Diseases (WHO Collaborating Centre, University of Sheffield Medical School, UK
Singapore Med J 43:100-5. 2002..The impact of BMD, age and other risks on fracture probability have recently been determined and provide a mechanism for optimising assessment of patients so that treatments can be efficiently directed to those most in need...
Treatment of malignant hypercalcaemia with aminohexane bisphosphonate (neridronate)E V McCloskey
Department of Human Metabolism and Clinical Biochemistry, University of Sheffield, UK
Br J Cancer 69:914-7. 1994..We conclude that aminohexane bisphosphonate is an effective agent in the treatment of tumour-induced hypercalcaemia, with rapid onset of effect and low toxicity...
Rationale for the use of bisphosphonates in breast cancerJ A Kanis
Department of Human Metabolism and Clinical Biochemistry, University of Sheffield Medical School, UK
Acta Oncol 35:61-7. 1996..Given, however, the unchanging survival in patients with metastatic bone disease, significant improvements in the quality of remaining life is an important therapeutic effect...
Effective treatment of malignant hypercalcaemia with a single intravenous infusion of clodronateE V McCloskey
Department of Human Metabolism and Clinical Biochemistry, University of Sheffield Medical School, UK
Br J Cancer 67:560-3. 1993..The single infusion has a more rapid onset of effect, is more convenient than multiple infusions, and has no adverse effect on renal function...
Atypical familial Paget's disease of boneK C Pande
WHO Collaborating Centre for Metabolic Bone Diseases, Royal Hallamshire Hospital, Sheffield, UK
Joint Bone Spine 68:257-61. 2001..We report unusual clinical and radiological features of Paget's disease of bone in three family members. All three patients had satisfactory biochemical and symptomatic response to treatment with an intravenous bisphosphonate (clodronate)...
